Assessing the Role of the Interleukin-12/STAT4 Axis in Breast Cancer by a Bioinformatics Approach

Area of Science:

• Immunology
• Oncology
• Genetics

Background:

• Interleukin-12 (IL-12) is an anti-tumor cytokine crucial for immune responses via the IL-12/STAT4 axis.
• Breast cancer (BC) is molecularly diverse, with varying immune microenvironments impacting treatment outcomes.
• The role of the IL-12/STAT4 axis in breast cancer subtypes remains largely unexplored.

Purpose of the Study:

• To investigate the association between the IL-12/STAT4 signaling axis and survival rates in breast cancer patients.
• To analyze this correlation across different molecular subtypes of breast cancer.
• To explore the potential of the IL-12/STAT4 axis in breast cancer prognosis.

Main Methods:

• Bioinformatics analysis utilizing The Cancer Genome Atlas (TCGA) database.
• Evaluation of gene expression levels of key IL-12/STAT4 pathway components (IL-12 receptor genes, STAT4, IFNG, TBX21).
• Correlation analysis between gene expression and patient survival data, stratified by breast cancer molecular subtypes.

Main Results:

• Elevated expression of IL-12/STAT4 pathway genes (IL12RB1, IL12RB2, STAT4, IFNG, TBX21) was significantly linked to improved survival in breast cancer patients.
• This positive correlation was particularly pronounced in aggressive subtypes: Luminal B (LumB), HER-2-positive, and Basal-like (BL).
• The findings suggest a potential subtype-specific role for the IL-12/STAT4 axis in breast cancer.

Conclusions:

• The IL-12/STAT4 signaling axis appears to play a significant role in breast cancer patient survival.
• Its influence may be specific to distinct molecular subtypes of breast cancer.
• Further research into the IL-12/STAT4 axis in breast cancer could inform the development of novel IL-12-based immunotherapies.